Belgian value-added medicines specialist Hyloris Pharmaceuticals has bolstered its management team with the appointment of a chief operating officer, shortly after receiving eight European approvals for its Maxigesic IV pain treatment.

With the main aim of developing its existing product portfolio and pursuing business development opportunities in the US, Hyloris Pharmaceuticals has successfully raised €80m through a public listing. The company has announced its financial results for the first half of 2020.